

**PUBLICATIES VAN DE ONDERZOEKSGROEPEN VAN**

**UA**

**Prof. Christine VAN BROECKHOVEN**

**UCL**

**Prof. André Goffinet and Dr. Emmanuel Hermans.**

**ULB**

**Prof. Marc Parmentier, Prof. Serge Schiffmann  
and Prof. Pierre Vanderhaeghen.**

**ULg**

**Prof. Pierre Maquet**

**UMons**

**Dr Laurence Ris**

**GESTEUND MET KREDIETEN VAN DE**

**GENEESKUNDIGE STICHTING KONINGIN ELISABETH**

**2008**

**VOLUME II**

**Prof. Dr. Christine VAN BROECKHOVEN**

CRUTS,M., VAN BROECKHOVEN,C.

**Loss of progranulin function in frontotemporal lobar degeneration.**

Trends in Genetics 24(4): 186-194 (2008) (PMID: 18328591) (I.F.: 8.659)

NUYTEMANS,K., PALS,P., SLEEGERS,K., ENGELBORGH,S., CORSMIT,E., PEETERS,K., PICKUT,B., MATTHEIJSENS,M., CRAS,P., DE DEYN,P., THEUNS,J., VAN BROECKHOVEN,C.

**Progranulin variability has no major role in Parkinson disease genetic etiology.**

Neurology 71: 1147-1151 (2008) (PMID: 18838661) (I.F.: 7.043)

VAN DER ZEE,J., SLEEGERS,K., VAN BROECKHOVEN,C.

**Invited article: the Alzheimer's disease - frontotemporal lobar degeneration spectrum.**

Neurology 71: 1191-1197 (2008) (PMID: 18838666) (I.F.: 7.043)

BROUWERS,N., SLEEGERS,K., ENGELBORGH,S., MAURER-STROH,S., GIJSELINCK,I., VAN DER ZEE,J., PICKUT,B., VAN DEN BROECK,M., MATTHEIJSENS,M., PEETERS,K., SCHYMKOWITZ,J., ROUSSEAU,F., MARTIN,J-J., CRUTS,M., DE DEYN,P., VAN BROECKHOVEN,C.

**Genetic variability in *progranulin* contributes to risk for clinically diagnosed Alzheimer disease.**

Neurology 71(9): 656-664 (2008) (PMID: 18565828) (I.F.: 7.043)

GIJSELINCK,I., VAN BROECKHOVEN,C., CRUTS,M.

**Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update.**

Human Mutation 29(12): 1373-1386 (2008) (PMID: 18543312) (I.F.: 7.033)

SLEEGERS,K., KUMAR-SINGH,S., CRUTS,M., VAN BROECKHOVEN,C.

**Molecular pathogenesis of frontotemporal lobar degeneration.**

Archives of Neurology 65(6): 700-704 (2008) (I.F.: 5.874)

**Prof. Dr. André GOFFINET**

L. ZHOU, I. BAR, Y. ACHOURI, K. CAMPBELL, O. DE BACKER, J. M. HEBERT, K. JONES, N. KESSARIS, C. LAMBERT de ROUVROIT, D. O'LEARY, W.D. RICHARDSON, F. ISSIR and A. GOFFINET.

**Early forebrain wiring: genetic dissection using conditional *Celsr3* mutant mice.**

Science, Vol. 320, pp. 946-949. **Impact Factor: 26,372.**

**Dr. Emmanuel HERMANS**

VANHOUTTE N., HERMANS E.

**Glutamate-induced glioma cells proliferation is prevented by functional expression of the glutamate transporter GLT-1.**

FEBS Letters., Vol. 582, pp 1847-1852. **Impact Factor 2008: 3.264**

BOUCHERIE C., CAUMONT A.S., MALOTEAUX J.M., HERMANS E.

**In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a transgenic rat model of familial amyotrophic lateral sclerosis (*hSOD1<sup>G93A</sup>*).**

Exp. Neurol., Vol. 212, pp 557-561 **Impact Factor 2008: 3.974**

**Prof. Dr. Marc PARMENTIER**

MALIKA EL YACOUBI, CATHERINE LEDENT, MARC PARMENTIER, JEAN COSTENTIN, JEAN-MARIE VAUGEOIS.

**Evidence for the involvement of the adenosine A<sub>2A</sub> receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine**

Neuropharmacology, Vol.55, pp. 35–40. **Impact Factor: 3.860** .

HUBERT GAERTNER, OLIVIER LEBEAU, IRENE BORLAT, FABRICE CERINI, BRIGITTE DUFOUR, GABRIEL KUENZI, ASTRID MELOTTI, RICHARD J. FISH, ROBIN OFFORD, JEAN-YVES SPRINGAEL, MARC PARMENTIER, AND OLIVER HARTLEY.

**Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 $\beta$ /CCL4**

Protein Engineering, Design & Selection, Vol. 21, nr. 2, pp. 65–72. **Impact factor: 3,000**.

A CASTANE', L WELLS, G SORIA, S HOURANI, C LEDENT, I KITCHEN, J OPACKA-JUFFRY, R MALDONADO AND O VALVERDE.

**Behavioural and biochemical responses to morphine associated with its motivational properties are altered in adenosine A<sub>2A</sub> receptor knockout mice**

British Journal of Pharmacology, Vol. 155, pp. 757–766. **Impact Factor: 3,825**.

A.GUILLABERT, V. WITTAMER, B. BONDUE, V. GODOT, V. IMBAULT, D. COMMUNI and M. PARMENTIER.

**Role of neutrophil proteinase 3 and mast cell chymase in chemerin proteolytic regulation.**

Journal of Leukocyte Biology, Vol. 84, pp. 1530-1539. **Impact factor: 4,572**.

**Prof. Dr. Serge N. SCHIFFMANN**

K. BANTUBUNGI, D. BLUM, L. CUVELIER, S. WISLET-GENDEBIEN, B. ROGISTER, E. BROUILLET, S.N. SCHIFFMANN.

**Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease.**

Molecular and Cellular Neuroscience, Vol.. 37, pp. 454-470. **Impact Factor: 4,607**.

N. GASPARD, T. BOUSCHET, R. HOUREZ, J. DIMIDSCHTEIN, G. NAEIJE, J. VAN DEN AMEELE, I. ESPUNY-CAMACHO, A. HERPOEL, L. PASSANTE, A. GAILLARD, P. VANDERHAEGHEN and S.N. SCHIFFMANN.

**An intrinsic mechanism of corticogenesis from embryonic stem cells.**

Nature, Vol. 455, pp. 351-357. **Impact Factor: 31,434**.

S. FERRE, C. QUIROZ, A.S.WOODS, R. CUNHA, P.POPOLI, F. CIRUELA, C. LLUIS, R. FRANCO, K. AZDAD, S.N. SCHIFFMANN.

**An update on adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor interactions: Implications for the function of G protein-coupled receptors.**

Current Pharmaceutical Design, Vol. 14, pp. 1468-1474. **Impact Factor: 5,270**.

E. GUNTZ, H. DUMONT, E. PASTIJN, A. DE KERCKHOVE D'EXAERDE, K. AZDAD, M. SOSNOWSKI, D. GALL and S.N. SCHIFFMANN.

**Expression of adenosine A<sub>2A</sub> receptors in the rat lumbar spinal cord and implications in the modulation of N-methyl-D-Aspartate receptor currents.**

Anaesthesia and Analgesia, Vol. 106, pp. 1882-1889. **Impact Factor: 2,131**.

**Prof. dr. Pierre VANDERHAEGHEN**

GASPARD N, BOUSCHET T, HOUREZ R, DIMIDSCHSTEIN J, NAEIJE G, VANDENAMEELE J, ESPUNY-CAMACHO I, HERPOEL A, PASSANTE L, SCHIFFMANN S, GAILLARD A, AND VANDERHAEGHEN P.

*With acknowledgement of a UCB Neuroscience Award.*

**An intrinsic mechanism of corticogenesis from embryonic stem cells**

Nature, Vol. 455, pp. 351-357. **Impact Factor: 30,00.**

PASSANTE L, GASPARD N, DEGRAEVE M, FRISEN J, KULLANDER K, DEMARTELAER V, AND VANDERHAEGHEN P.

*With acknowledgement of a UCB Neuroscience Award.*

**Temporal regulation of ephrin/Eph signalling is required for the spatial patterning of the mammalian striatum.**

Development, Vol. 135, pp. 3281-3290. **Impact Factor: 8,00;**

ROSSO L, MARQUES AC, WEIER M, LAMBERT N, LAMBOT MA, VANDERHAEGHEN P, AND KAESSMANN H.

**Birth and rapid sub cellular adaptation of a hominoid-specific CDC14 protein.**

PLoS Biol, Vol.. 6, e140. **Impact Factor: 12**

**Prof. Dr. Pierre MAQUET**

L. MATARAZZO, E. FRANKÓ, R. VOGELS and P. MAQUET.

**Offline processing of memories induced by perceptual visual learning during subsequent wakefulness and sleep: a behavioral study.**

Journal of Vision, Vol. 8, Nr.4, pp. 1-9. **Impact Factor: 3,791.**

G. ALBOUY, V. STERPENICH, E. BALTEAU, G. VANDEWALLE, M. DESSEILLES, THANH DANG-VU, A. DARSAUD, P. RUBY, P.-H. LUPPI, C. DEGUELDRE, P. PEIGNEUX, A. LUXEN and P. MAQUET.

**Both the hippocampus and striatum are involved in consolidation of motor sequence memory.**

Neuron, nr. 58, pp. 261-272. **Impact Factor: 14,170.**

M. BOLY, C. PHILIPS, L. TSHIBANDA, A. VANHAUDENHUYSE, M. SCHABUS, T.T. DANG-VU, G. MOONEN, R. HUSTINX, S. LAUREYS and P. MAQUET.

**Intrinsic brain activity in altered states of consciousness.****How conscious is the default mode of brain function.**

Annual N.Y. Acad. Science, nr. 1129, pp. 119-129. **Impact Factor: 2,383.**

P. BOVEROUX, V. BONHOMME, M. BOLY, A. VANHAUDENHUYSE, S. LAUREYS and P. MAQUET.

**Brain function in physiologically, pharmacologically and pathologically altered states of consciousness.**

International Anesthesiology Clinics, Vol. 46, nr. 3, pp. 131-146. **Impact Factor:**

T. DANG-VU, M. SCHABUS, M. DESSEILLES, G. ALBOUY, M. BOLY, A. DARSAUD, S. GAIS, G. RAUCHS, V. STERPENICH, G. VANDEWALLE, J. CARRIER, G. MOONEN, E. BALTEAU, C. DEGUELDRE, A. LUXEN, C. PHILIPS and P. MAQUET.

**Spontaneous neural activity during human slow wave sleep.**

PNAS, Vol. 105, nr. 39, pp. 15160-15165. **Impact Factor: 9,380.**

D. HAIBO, M. BOLY, W. WENG, D. LEDOUX and S. LAUREYS.

**Neuroimaging activation studies in the vegetative state: predictors of recovery.**

Clinical Medicine, Vol. 8, nr. 5, pp. 502-507. **Impact Factor: 1,217.**

O. GOSSERIES, A. DEMERTZI, Q. NOIRHOMME, J. TSHIBANDA, M. BOLY, M. OP DE BEECK, R. HUSTINX, P. MAQUET, E. SALMON, G. MOONEN, A. LUXEN, S. LAUREYS and X. DE TIÈGE.

**Que mesure la Neuro-imagerie fonctionnelle: IRMf, TEP & MEG ?**

Revue Médical Liège, Vol. 63, nr.5-6, pp. 231-237.

M. KIRSCH, P. BOVEROUX, P. MASSION, B. SADZOT, M. BOLY, B. LAMBERMONT, M. LAMY, P. DAMAS, F. DAMAS, G. MOONEN, S. LAUREYS and D. LEDOUX.

**Comment prédire l'évolution du coma post-anoxique.**

Revue Medical Liège, Vol. 63, nr.5-6, pp. 263-268.

S. LAUREYS and M. BOLY.

**The changing spectrum of coma.**

Nature Clinical Practice Neurology, Vol. 4, nr. 10, pp.544-546. **Impact Factor: 6.979.**

D. LEDOUX, S. PIRET, P. BOVEROUX, M.-A. BRUNO, A. VANHAUDENHUYSE, P. DAMAS, G. MOONEN and S. LAUREYS.

**Les échelles d'évaluation des états de conscience altérée.**

**Clinical evaluation of consciousness in the acute setting.**

Reanimation, Vol. 17, pp; 695-701. Impact Factor:

M. BOLY, M-E. FAYMONVILLE, C. SCHNAKERS, P. PEIGNEUX, B. LAMBERMONT, C. PHILLIPS, P. LANCELLOTTI, A. LUXEN, M. LAMY, G. MOONEN, P. MAQUET and S. LAUREYS.

**Perception of pain in the minimally conscious state with PET activation: an observational study.**

The Lancet, October 2008, pp. 1-8. **Impact Factor: 14,270.**

G. RAUCHS, P. ORBAN, E. BALTEAU, C. SCHMIDT, C. DEGUELDRE, A. LUXEN, P. MAQUET and P. PEIGNEUX.

**Partially segregated neural networks for spatial and contextual memory in virtual navigation.**

Hippocampus, Vol. 18, pp. 503-518. **Impact Factor: 5,230.**

M. THONNARD, C. SCHNACKERS, M. BOLY, M.A. BRUNO, P. BOVEROUX, S. LAUREYS, and A.VANHAUDENHUYSE

**Expériences de mort imminente: Phénomènes paranormaux ou neurologiques.**

Revue Médical Liège, Vol. 63, pp. 438-444.

**Dr. Laurence RIS**

DEWACHTER I, S. CROES, P. BORGHGRAEF, H. DEVIJVER, T. VOETS, B. NILIUS, F. VAN LEUVEN, E. GODAUX and L. RIS.

**Modulation of synaptic plasticity and tau phosphorylation by wild-type and mutant presenilin1.**

Neurobiology of aging, Vol. nr 29, pp. 639-652. **Impact Factor: 5,900.**